Bone & Joint Research

Supplementary Material

Table i. Primer sequences for human quantitative reverse transcription polymerase chain reaction.

Gene	Primer sequences (5' to 3')
miR-183	Forward: GCGGCGGTATGGCACTGGTAGA
	Reverse: GCGGGTGCAGGGTCCGAGGT
TGFα	Forward: AATCCATCAGCAGGGATCTG
	Reverse: GATTTGGCCTGAAATGCCTA
CCL2	Forward: CAGCCAGATGCAATCAATGCC
	Reverse: TGGAATCCTGAACCCACTTCT
CCR2	Forward: TTGTGGGCAACATGATGG
	Reverse: CTGTGAATAATTTGCACATTGC
U6	Forward: CTCGCTTCGGCAGCACA
	Reverse: AACGCTTCACGAATTTGCGT
GAPDH	Forward: ACCTGCCAAATATGATGACATC
	Reverse: GTATCCAGTGCAGGGTCC

CCL2, C-C motif chemokine ligand 2; CCR2, C-C chemokine receptor 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; miR-183, microRNA-183; TGFα, transforming growth factor α.

Table ii. Mouse primer sequences for quantitative reverse transcription polymerase chain reaction.

Gene	Primer sequences (5' to 3')
miR-183	Forward: CGCGTATGGCACTGGTAGAA
	Reverse: AGTGCAGGGTCCGAGGTATT
TGFα	Forward: TGATACACTGCTGCCAGGTC
	Reverse: ATCTCTGGCAGTGCTGTCCT
TNF-α	Forward: CTGAACTTCGGGGTGATCGG
	Reverse: GGCTTGTCACTCGAATTTTGAGA
IL-1β	Forward: ATGGCAGAAGTACCTAAGCTCGC
	Reverse: ACACAAATTGCATGGTGAAGTCAGTT
IL- 6	Forward: ATGAACTCCTTCTCCACAAGCGC
	Reverse: GAAGAGCCCTCAGGCTGGACTG
TRPV1	Forward: GTGGACAGCTACAGTGAGATAC
	Reverse: CACCATGGAAGCCACATACT
Nav1.3	Forward: AGCTTGGCCTGGCAAACGTG
	Reverse: ATGCCGACCACGGCAAAAATG
Nav1.7	Forward: ACGGATGAATTCAAAAATGTACTTGCAG
	Reverse: GTTCTCGTTGATCTTGCAAACACA
Nav1.8	Forward: ACCGACAATCAGAGCGAGGAG
	Reverse: ACAGACTAGAAATGGACAGAATCACC
U6	Forward: CTCGCTTCGGCAGCACA
	Reverse: AACGCTTCACGAATTTGCGT
GAPDH	Forward: ACCTGCCAAATATGATGACATC
	Reverse: GTATCCAGTGCAGGGTCC

GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL, interleukin; miR-183, microRNA-183;

Nav1.3, voltage-gated sodium 1.3; Nav1.7, voltage-gated sodium 1.7; Nav1.8, voltage-gated sodium

1.8; TGFα, transforming growth factor α; TNF-α, tumour necrosis factor-α; TRPV1, transient receptor

potential vanilloid subtype-1.

Fig. a. Mechanistic diagram illustrating how microRNA-183 (miR-183) ameliorates osteoarthritis (OA) pain by inhibiting the TGFα–CCL2/CCR2 signalling axis. CCL2, C-C motif chemokine ligand 2; CCR2, C-C chemokine receptor 2; IL, interleukin; Nav1.3, voltage-gated sodium 1.3; Nav1.7, voltage-gated sodium 1.7; Nav1.8, voltage-gated sodium 1.8; TGFα, transforming growth factor α; TNF-α, tumour necrosis factor-α; TRPV1, transient receptor potential vanilloid subtype-1.